Research programme: pain therapeutics - Cameleon/NeuroSolutions
Alternative Names: NSL-105Latest Information Update: 16 Jul 2016
At a glance
- Originator Cameleon; NeuroSolutions
- Developer NeuroSolutions
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neuropathic pain; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in United Kingdom